FIELD: biotechnology.
SUBSTANCE: described is a group of inventions involving the use of a bispecific antigen-binding molecule to CD3/PSMA and 4-1BB agonist for treating PSMA-positive cancer or inhibiting the growth of a PSMA-positive tumour, use of a bispecific antigen-binding molecule to CD3/PSMA and 4-1BB agonist to increase multiplication of CD8 + T-cells in PSMA-positive tumour tissue, use of a bispecific antigen-binding molecule to CD3/PSMA and 4-1BB agonist to initiate and/or enhance a T-cell response to a PSMA-positive tumour and a pharmaceutical combination for treating PSMA-positive cancer or inhibiting the growth of a PSMA-positive tumour, increasing CD8+ T-cell proliferation in the PSMA-positive tumour tissue and/or initiating and/or enhancing the T-cell response to the PSMA-positive tumour.
EFFECT: invention extends the range of products for treating PSMA-positive cancer or inhibiting the growth of PSMA-positive tumour, increase of CD8+ T-cell multiplication in PSMA-positive tumour tissue and/or initiation and/or intensification of T-cell response in relation to PSMA-positive tumour.
34 cl, 7 dwg, 2 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| USE OF BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND MUC16 AND CD3, IN COMBINATION WITH COSTIMULATION 4-1BB | 2020 |
|
RU2822091C2 |
| NEW PSMA-BINDING ANTIBODY AND ITS APPLICATIONS | 2017 |
|
RU2762704C2 |
| ANTIBODIES BINDING CD3 | 2017 |
|
RU2790288C2 |
| CD3 BINDING ANTIBODIES | 2017 |
|
RU2807216C2 |
| MOLECULES WHICH BIND TO 4-1BB | 2011 |
|
RU2710717C2 |
| HER-2-DIRECTED ANTIGEN-BINDING MOLECULES CONTAINING 4-1BBL | 2019 |
|
RU2815451C2 |
| BIOSPECIFIC ANTIGEN-BINDING MOLECULES | 2012 |
|
RU2650775C2 |
| METHODS FOR TREATING CANCER, INCLUDING TIGIT-BINDING AGENTS | 2017 |
|
RU2765410C2 |
| BISPECIFIC ANTIBODIES TO CD25 AND Fc GAMMA-RECEPTOR FOR ELIMINATION OF TUMOR-SPECIFIC CELLS | 2017 |
|
RU2759970C2 |
| PSMA×CD3 BISPECIFIC SINGLE-CHAIN ANTIBODY HAVING INTERSPECIES SPECIFICITY | 2009 |
|
RU2559531C2 |
